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1. Introduction 
Allergic diseases are an adverse reaction of the immune system against otherwise innocuous 
substances and are characterized by their high complexity. Patients can be asymptomatic or 
their involvement could be as severe as asthma. The complex nature of the phenotypes 
involved seems to point to genetic and environmental factors implication.  
Familiar aggregation or genetic implication in the development of these diseases is well 
reported, and experts seem to agree that atopic diseases affect homozygotic twins more than 
dizigotic twins (Ownby, 1990, Duffy et al., 1990).  
Allergic diseases are characterized by a Th2 inflammatory response involving several 
possible modulator factors (genetics and environmental factors), subject-related or antigen-
related modulators such as adjuvants, solubility in the microenvironment of mucosa, size of 
the sensitization agent, mucosa permeability, viral infections, and the greater or lesser 
ability of effectors cells to liberate mediators. 
Other factors include atmospheric pollution, exposure to tobacco, lifestyle-related diet and 
hygiene habits and maternal effects. The interaction between these factors produces the 
clinical picture of allergic disease. 
Great advances have been performed in the understanding, diagnosis and treatment of these 
diseases but the search of specific protective or risk biomarkers is an unsolved field.   
Since completion of the human genome project a rapid progress in genetics and 
bioinformatics have enabled the development of multiple tools as well as a large public 
databases, which include genetic and genomic data linked to clinical health data. The 
scientific revolution represented by the description of the human genome was largely 
facilitated by the use of DNA microarray technology, which made it possible to build a 
catalog of all genes within a given organism. The human genome project found that humans 
have an average of between 20,000 and 25,000 protein-coding genes (IHGSC, 2004). In 
addition, genetic variability between individuals is approximately 1% (Venter et al., 2001), 
suggesting that interactions between genes, proteins and the environment contribute to 
differences in human phenotype, maintenance of health and susceptibility to disease. On the 
other hand, the emergence of gene expression microarray technology in the mid-1990s has 
enabled genome-wide measurement of gene expression in a single experiment. This is turn 
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has allowed for significant advances in our understanding of gene expression, regulation, 
and function and continues to serve as an important tool in basic science research. This 
novel technology was subsequently extended from molecular genetics to proteomics, 
allowing the start of the Human Proteome Project, designed to determine protein function 
as essential elements in diagnosis and treatment.  
Mainly, the genome project has fundamentally changed the way in which we approach 
questions in biology. The technology that the genome project has enabled, rather than the 
data it has produced, has induced the most profound impact on our conduct of biological 
research. In particular, functional genomics approaches, suchs as DNA microarrays, 
proteomics and metabolomics have greatly increased the rate at which we can generate data 
on biological systems allowing us, to begin to observe on a molecular level the holistic 
response of an organism to a particular stimulus (Quackenbush, 2006).  
In this review, will be summarize the principle of these new methodologies and the impact 
of omics-techniques, mainly genomic-transcriptomics (analysis of single nucleotide 
polymorphisms or gene-expression) and proteomic (identification and quantification of 
proteins), in the knowledge of different aspects of allergy diseases (diagnosis, screening, 
monitoring of treatment, protective or risk biomarkers and drug development) and the 
advance to define the personalized and molecular medicine in this complex kind of diseases. 
2. High-throughput technologies: “Omics approaches” review 
During the last decade, high-throughput technologies including genomic, transcriptomic, 
epigenomic, and proteomic have been applied to further our understanding of molecular 
pathogenesis of heterogeneous disease, and to develop strategies that aim to improve the 
management of patients. These approaches called omics should lead to sensitive, specific 
and non-invasive methods for early diagnosis, and facilitate the prediction of response to 
therapy and outcome, as well as the identification of potential novel therapeutic targets 
(Ocak et al., 2009). 
Omics approaches to the study of complex biological systems with potential applications to 
molecular medicine are attracting great interest in clinical as well as in basic biological 
research. Genomics, transcriptomics and proteomics are characterized by the lack of an a 
priori definition of scope, and this gives sufficient leeway for investigators (a) to discern all 
at once a globally altered pattern of gene/protein expression and (b) to examine the 
complex interactions that regulate entire biological processes (Silvestri et al., 2011). All 
classes of biological compounds, from genes through mRNA to proteins and metabolites, 
can be analyzed by the respective “omic” approaches, namely, genomics (Study of genomes 
and the complete collection of genes that they contain), transcriptomics (or functional 
genomics, attempts to analyze patterns of gene expression and to correlate the patterns with 
the underlying biology), epigenomic (the large-scale study of epigenetic modifications), 
proteomics (examine the collection of proteins to determine how, when and where they are 
expressed) or metabolomics (or metabonomics, is a large-scale approach to characterize and 
to quantify the compounds involved in cellular processes in a single assay to derive 
metabolic profiles). Such an “omic” approach leads to a broader view of the biological 
system, including the pathology of diseases. 
Two popular platforms in “omics” are DNA microarray, which measure messenger RNA 
transcript levels, and proteomic analyses, which identify and quantify proteins. Because of 
their intrinsic strengths and weaknesses, no single approach can fully unravel the 
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complexities of fundamental biological events. However, an appropriate combination of 
different tools could lead to integrative analyses that would furnish new insights not 
accessible through one-dimensional datasets (Silvestri et al., 2011). Indeed, while the data 
obtained from genomics may explain the disposition of diseases (i.e., increasing risk of 
acquiring a certain disease), several other mechanisms that are not gene mediated may be 
involved in the onset of disease.  
Genomic studies were the first to move this field forward by providing novel insights into 
the molecular biology of cancer by generating candidate biomarkers of disease progression. 
Epigenetic regulation by DNA methylation and histone modifications modulate chromatin 
structure and, in turn, either activate or silence gene expression. Proteomic approaches 
critically complement these molecular studies, as the phenotype is determined by proteins 
and cannot be predicted by genomics or transcriptomics alone. Indeed, expression levels of 
proteins are commonly subject to post-transcriptional modifications that may modify their 
functions.  
Moreover, a single gene can be processed to result in several different mRNAs or proteins, 
which directly determine different cellular functions. Genomic and proteomic data analyses 
have proven to be essential for an understanding of the underlying factors involved in 
human disease and for the discovery of diagnostic biomarkers, as well as for the provision 
of further insights into signalling molecules. 
Therefore, while genomics/transcriptomics enables assessments of all potential information, 
proteomics enables us to assess the programs that are actually executed, and metabolomics 
will mostly display the results of such executions. 
In the postgenomic era, functional analysis of genes and their products constitutes a novel 
and powerful approach since the expression levels of multiple genes and proteins can 
thereby be analyzed simultaneously, in both health and disease. Among the techniques used 
in functional genomics, both DNA microarrays and classical and ongoing proteomic 
approaches hold great promise for the study of complex biological systems and have 
applications in molecular medicine. These technologies allow high-throughput analysis as 
they are complementary to each other, and they may lead to a better understanding of the 
regulatory events involved in physiological, and disease, processes.  
2.1 Genomic 
Genomic provides us with platforms to measure quantitatively the essential elements 
(genes) of the cell and includes haplotyping and single nucleotide polymorphism detection. 
Is the study of an organism’s entire genome. Some of the most important of the related 
technologies are high-throughput capillary sequencing and single-nucleotide polymorphism 
(SNP) arrays. 
2.1.1 Global genome sequencing 
This method has made major improvements from gel-based sequencing to automated 
reading of the four nucleotides (TGCA) (Wheeler et al., 2008, Wang J et al., 2008, Levy et al., 
2007), by sequencing-by-synthesis technology that binds short fragments of DNA to small 
beads that are dropped into wells in a fibreoptic chip. The DNA adds another molecule to its 
chain and the sequencer identifies the molecule used, indicating which base is next in the 
sequence. Although the assemble of these pieces of DNA is a major challenge and may 
require multiple runs through a sequencer before assembling all the sequence, the use of 
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capillary electrophoresis instead of a gel, has allowed the automation DNA loading system, 
leading to and increase in throughput and higher speeds. 
The systematic re-sequencing of genes tumours has provided in cancer field a rich source of 
clinically relevant information increasing the discovery of critical mutations as has been 
revised by Ocak et al., 2009. 
2.1.2 SNP arrays 
These arrays allow accurate measurement of specific loss of heterozygosity in a high-
throughput manner with the possibility to identify patterns of allelic imbalance and small 
regions of copy number alterations, with potential prognosis and diagnostic utilities. They 
are synthesised by photolithography and contain up to 40 separate oligonucleotide probes 
for each SNP locus, with up 2 million SNP loci formats. After DNA labelling and 
hybridisation, fluorescence intensities are measured for each allele of each SNP. 
This methodology is mainly used in the genome-wide association studies (GWASs) using 
case-control or case-only approaches. GWAS approaches are based on the ability to rapidly 
analyze genetic variants (mainly single nucleotide polymorphisms [SNPs], usually with a 
high degree of heterozygosity) across the whole genome to determine which genetic 
variants are associated with disease susceptibility (case-control studies) or which are 
associated with measures of disease severity or response to treatment (ie, pharmacogenetics; 
case-only studies). GWASs are also performed in families, especially trios, which are defined 
as an affected child with genotyping from both parents (eg, the National Heart, Lung, and 
Blood Institute [NHLBI]'s Childhood Asthma Management Program study identified PDE4 
(Himes et al., 2009) as an asthma susceptibility gene) but it is generally easier to ascertain 
and characterize a large number of unrelated cases and control subjects than to study 
multiple family members (Meyers, 2010). 
The basic principle of a GWAS is straightforward: the frequency of each genetic variant is 
compared between cases (ie, subjects with the disease under investigation) and control 
subjects without the disease. A statistically significant increased frequency in cases 
compared with control subjects provides evidence that the genetic variant is related to 
disease susceptibility. Because many genetic variants (SNPs) are tested (usually 300,000 to 1 
million), adjustment for multiple testing is required; for example, in the National Institutes 
of Health catalog of GWAS results, only those with P values of 5 × 10−8 or less are included 
in their chromosomal map of association results from many common diseases 
(www.genome.gov/GWAS). 
The results from GWASs are the first step. Replication studies are necessary, and meta-
analyses are useful to determine the importance of these variants in multiple populations.  
2.2 Transcriptomic 
Transcriptomic afford information about the expression of individual genes at the 
messenger RNA (mRNA) levels. 
Is the study of global analysis of gene expression or transcriptome, the complete set of 
mRNA transcript produced by the genome. The most common related high-throughput 
technologies are gene expression arrays or microRNA (miRNA) expression arrays. 
2.2.1 Gene expression arrays  
This methodology derivate from two families of technologies: the first for nucleic acid 
detection and the second for the development of multiplex solid-phase assays (Patel A, 
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2008). The technique for detection of specific nucleic acid sequences by hybridization of 
labels nucleic acid sequences to known sequences immobilized on a solid support was 
developed initially for DNA detection (Southern, 1975), adapted for messenger RNA 
detection (Alwine et al., 1977) (Northern blot), and modified for placing the detection 
reagent (antibody or nucleic acid probe) on the solid support and leave the analyte in the 
liquid phase (eg, reverse Northern blot, dot blot)(Catt et al.,1966, Engvall et al., 2005, Kafatos 
et al., 1979). 
The next significant technological development was the description of a system for detecting 
multiple analytes via the use of microspots (Ekins et al, 1990, 1999). Each microspot would 
contain a capture antibody to bind the analyte if present. A second antibody would be used 
to detect the presence of bound sensor antibody. If labelled fluorescently with different 
fluorophores, the ratio of fluorescence intensity between bound and unbound sensor 
antibody could be determined by laser scanning confocal microscopy, and with appropriate 
standards, this could be used to precisely quantify the amount of a given analyte. These 
were in essence the microarrays bases, the microspots, the bound detection reagent and the 
fluorescent readout.  
However, several new technologies and information resources were required, mainly 
related with the improvement in the platforms, with the use of impermeable support 
materials (smaller amount of probe material), the increase of information from probes used 
for each target (derived from sequencing projects), system for detection of small amounts of 
labelled nucleic acid bound to complementary probes on small spots via confocal or non-
confocal laser scanning techniques, and especially image analysis and data analysis 
techniques, that represent a significant challenge given the large number of variables, which 
has led to multiple approaches for microarrays data analysis (Patel A, 2008). 
These arrays mostly make use of matrix-bound probes to which processed mRNA templates 
of the analysed specimens will hybridise. Two major types of arrays have been developed: 
oligonucleotide (use short oligonucleotides synthesised on the array matrix) and cDNA 
arrays (employs probes of copy-DNA).  
There are two basic approaches to generate microarray data ( Quackenbush, 2006). In a two-
color array, two samples of RNA, each labelled with a different dye, are simultaneously 
hybridized to the array. Such an assay compares paired samples and reports expression as 
the logarithms of the ratio of RNA in a query sample to that in a control sample. For single-
colour arrays, such as the GeneChip (Affymetrix), each sample is labelled and individually 
incubated with an array. After non-hybridized material in the sample is removed by 
washing, the level of expression of each gene is reported as a single fluorescence intensity 
that represents an estimated level of gene expression. Regardless of the approach or 
technique, the data used in all subsequent analyses are expression measures for each gene in 
each sample. Following hybridisation of a pre-processed and fluorescently labelled mRNA 
sample, the arrays are scanned and transcript abundance is measured as a direct correlate of 
signal intensity. After data normalisation, data can be analysed using a virtually unlimited 
array of computational and statistical methods. Normalization and filtering transformations 
must be carefully applied, because they can have a profound effect on the results. Different 
methods of statistical analysis applied to the same data set may produce different (but 
usually overlapping) sets of significant genes. 
To ease interpretation of the results of multiple hybridizations, elements of the data in a 
matrix are often rendered in colour, which indicates the level of expression of each gene in 
each sample and yields a visual representation of gene-expression patterns in the sample 
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being analyzed. In the most common approach, the colours used for the genes are based on 
the log-ratio for each sample measured as compared with a control sample : close to zero in 
black, values greater than zero in red (indicating up-regulated genes) and those with 
negative values in green (down-regulated genes). The intensity of each element, as 
compared with the intensities of others, indicates the relative expression of the gene that the 
element represents. 
After the appropriate data have been recorded, normalized and filtered and a means of 
measuring similarity has been chosen, a variety of approaches are available for further 
analysis. These approaches are generally grouped into two types: supervised and 
unsupervised methods. Supervised methods depend on prior knowledge about the samples 
in order to search for genes that correlate with a diseases state, and they are useful for 
classification studies and can yield gene sets or signatures of genes that can distinguish 
between a priori defined subsets of samples. Unsupervised methods disregard prior 
knowledge and can be useful for identifying subgroups of samples that may represent 
unrecognized disease states. This method allow self-organisation of data matrices, group 
samples (or genes, or both), according to similarity of expression profiles features. This 
approached can help identify subgroups of samples not known a priori that are characterised 
by a typical transcriptional signature.  
In order to minimise the risk of over fitting the predictive signature, such approaches 
typically involve validation of the predictor in a separate dataset or by splitting the original 
dataset into a learning and test set. In the latter case, the predictor is built using the learning 
set and then validated in the test set.  
The discovery of biomarker signatures or panels for diagnosis by non-invasive methods is 
crucial for some diseases, as lung cancer, reason why these methodologies are very 
important. Soon after microarrays were introduced, many researchers realized with this 
technique could be used to find new subclasses in diseases states (Alon et al., 1999, Perou et 
al., 1999) and identify biological markers (biomarkers) associated with disease (Moch et al., 
1999) and that even the expression patterns of genes could be used to distinguish subclasses 
of disease (Khan et al., 1998, Goiub et al., 1999, Bloom et al .,2004). 
Many early studies focused an unsupervised approach to data-mining, such as hierarchical 
clustering for class discovery, because such studies take an unbiased approach to searching 
for subgroups in the data. The analysis was useful in lymphoma (Alizadeh et al., 2000) for 
identifying two subclasses related to a different stage of B-cell differentiation and showed 
the distinct clinical progress. 
Other kind of studies (Golub et al., 1999) showed that microarray-expression profiles can be 
used to classify disease states. This kind of studies made clear that disease classification 
according to expression profiles will be come an important area of application for 
microarrays, proteomics, metabolomics and other high-throughput genomic techniques. The 
question is whether a pattern can be found that can be used to distinguish biological 
samples on the basis of some inherent property.  
As will be remarked in the specific paragraph, this is one of the high-throughput 
methodologies more used in allergy diseases studies and with more interesting advances. 
2.2.2 miRNA expression arrays 
miRNAs are single-stranded, small (18 to 24 nucleotides in length), noncoding RNAs that 
negatively regulate gene expression by binding to and modulating the translation of specific 
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mRNAs. It is estimated that miRNAs may be responsible for regulating the expression of 
nearly one-third of the human genome. Each miRNA appears to regulate the translation of 
multiple genes, and many genes appear to be regulated by multiple miRNAs. The 
methodology is like gene expression arrays by using arrays with up to 1300 distinct probes 
of eight to nine nucleotides (Ocak et al., 2009). 
Although is estimated that miRNAs may be responsible for regulating the expression of 
nearly one-third of the human genome, few studies have explored their relevance to the 
pathogenesis of diseases and specifically in lung diseases (review in Serge  et al., 2009). 
However, miRNA may be considered as potential therapeutic targets, as regulators of gene 
transcription and protein production and their study could be very useful for understanding 
human health and disease. 
2.3 Epigenomics 
The field of epigenetic has emerged to explain how cells with the same DNA can 
differentiate into alternative cell types and how a phenotype can be passed from one cell to 
its daughter cells (Baye et al., 2010). Unlike genetic alterations, which are permanent and 
usually affect all cells, epigenetic modifications are cell type specific and epigenetic 
regulation of immune system occurs at many levels, including T cells (Locksley, 2009, Wells, 
2009). Epigenetic effects on gene expression can persist even after removal of the inducing 
agent and can be passed on through mitosis to subsequent cell generations, constituting a 
heritable change (Baye et al., 2010). The role of epigenetic in diseases, and specifically in 
allergic diseases is becoming increasingly evident (review in Kumar et al., 2009).  
Recent development of epigenomic or the large-scale study by high-troughput/genome 
wide detection of epigenetic modifications, as heritable changes in gene expression without 
DNA sequence alterations, mainly DNA methylation and histone post-translational 
modification, should bring out more data relevant to allergic diseases. 
Different techniques coupled to high-throughput technologies are available for the detection 
of DNA methylation, based on the ability to distinguish cytosine from 5-methylcytosine in 
the DNA sequence. To study histone modifications, there is a microarray platform of 
chromatin immuno-precipitation-on chip that allow the assessment of chromatin states. 
It should be very interesting to know how genetics, environmental factors and epigenetics 
regulate each other for understanding the molecular events that underlie complex diseases 
such allergy diseases. 
2.4 Proteomics 
Is the large-scale study of proteins, particularly their structure and function. Proteomics 
focuses on determination of individual protein concentrations present in the biological 
sample being investigated, whereas functional proteomic determines constituent protein-
protein, protein-DNA, and protein-RNA interactions and their resulting complexes.  
Proteins are excellent targets in disease diagnostics, prognostics, and therapeutics. 
Consequently, proteomic approaches (such as two-dimensional gel electrophoresis (2D-E), 
two-dimensional liquid chromatography (2-DL), and mass spectrometry (MS), which allow 
the simultaneous measurement  and comparison of the expression levels of hundreds of 
proteins, represent powerful tools for (a) the discovery of novel hormone/drug targets and 
biomarkers and (b) studies of cellular metabolisms and protein expression (Righetti et al., 
2004, Vlahou et al., 2005). Increasingly, proteomic techniques are being adopted to solve 
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analytical problems and obtain a more comprehensive identification and characterization of 
molecular events associated with pathophysiological conditions.  
Several high-throughput technologies have been developed and a brief summary of the 
main technological characteristics is exposed.  
2.4.1 Two-dimensional gel electrophoresis  
This technique relies on polyacrilamide gels that separate proteins based first on their 
charge and then on their molecular weight. Gel are scanned with laser densitometers and 
analysed with software allowing the semiquantitative visualisation of >500-1000 proteins 
per gel (Bergman et al., 2000). Individual protein spots of interest can be digested into 
peptides for sequence analysis by mass spectrometry (MS). A modification of this technique 
is the differential in gel-electrophoresis (DIGE), used to compare two protein mixtures on 
the same gel, using different fluorescent dyes, mixed together and run on the same gel 
(Patton, 2002). Identical proteins from the two pools co-migrate and are independently 
detected by quantitative fluorometry. Differentially expressed proteins of interest are 
identified by alterations in the ratios of the two fluorescent signals.  
2.4.2 Matrix-assisted laser desorption ionisation time-of-flight MS (MALDI-TOF MS)  
Is a high-throughput technique that analyses with high sensitivity and specificity proteins 
expressed in complex biological mixtures, such as serum, urine and tissues (Caprioli et al., 
1997, Farmer et al., 1991). It requires sample co-crystallisation with a matrix that absorbs 
laser energy and subsequently ejects and ionises molecules into the gas phase. Ions are 
accelerated from the ion source by a fixed potential difference and travel a fixed-length, 
field-free distance before reaching the detector. The time taken by each ion permits its 
characterization. This methodology has been extensively applied to proteomic profiling of 
biological specimens. 
2.4.3 Liquid chromatography tandem MS  
This technique combines high-performance liquid chromatography (LC) with electrospray 
ionisation MS, ionising and vaporising proteins from liquid solutions. The shotgun proteomic 
analysis platform uses digestion of the sample with site-specific proteases, multidimensional 
separation of peptides by strong cation exchange chromatography (Link et al., 1999, Wolters et 
al., 2001, Cargile et al., 2004, Essader et al., 2005), followed by reverse phase LC separation 
coupled directly to a tandem MS instrument (MS/MS). The most abundant peptides are 
sequentially selected for MS/MS analyses. Resulting fragments ions are analysed in a MS scan 
and based on their molecular weight, the peptide sequence can be derived (Liebler, 2004). 
Through comparisons with predicted sequences of same nominal mass in databases, peptides 
are identified and the proteins from which they came are deduced. 
2.4.4 Protein arrays  
This is an efficient way of simultaneously analysing multiple samples or proteins in a high-
throughput manner. There are two main forms: 1. Forward-phase arrays where hundreds of 
specifics antibodies are arrayed on a glass slide and one complex protein sample could be 
analysed for expression levels of post-translational modifications of hundreds of proteins in 
a single experiments. 2. Reverse-phase arrays, where hundreds of proteins (natural or 
recombinants) are placed on glass slides and probed with a single sample.  
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Post-translational modifications of proteins, such as phosphorylation, glycosilation and 
proteolytic processing, are common events and have the potential to significantly modify 
protein functions as well as confer cellular or tissue specificity. Since these modifications are 
reversible, drugs inhibiting these modifications are developed and hold great promise for 
some therapies as lung cancer therapy. Proteomics strategies have an important role by 
allowing not only the identification of post-translational modifications, but also the 
quantification and monitoring of the changes induced by their regulators. 
2.5 Other complementary technologies 
2.5.1 Pharmacogenomics 
Is an emerging area of biomedical research, strongly influenced by growing availability of 
genomic databases, high-throughput genomic technologies, bioinformatics tools and artificial 
computational modelling approaches.  Pharmacogenomics offers a new tool for the discovery 
of new targets for drugs development purposes, and for the individual variation in drug 
response. One main area is the discovery of new drugs and drug targets with molecular 
genetic, genomic or even bioinformatics methods and the other is the study of how genomic 
differences influence the variability in patient´ responses to drugs. Genes that have been found 
implicated in the disease are potential new drug targets and several pharmacological 
investigations are underway to utilize these new discoveries (Szalai et al., 2008).  
2.5.2 Immunoinformatics, or computional immunology 
Is an emerging area that provides fundamental methodologies in the study of immunomics, 
that is, immune-related, genomics and proteomics. The integrations of immune informatics 
with system biology approach made lead to a better understanding of immune related 
diseases at various system levels. 
The information about genetic diversity of the immune system may help define patient’s 
subgroups for individualized vaccine or drug development. Cellular pathways and host 
immune-pathogens interactions have a crucial impact on disease pathogenesis and 
immunogen design. Epigenetic studies may help understand how environmental change 
influence complex immuno diseases such as allergy. High-throughput technologies enable 
the measurements and catalogue of genes, proteins, interactions, and behaviour. Such 
perception may contribute to the understanding of the interaction network among humans, 
vaccines and drug, to enable new insights of diseases and therapeutic responses. 
Bioinformatics plays an indispensable role in designing experiments, so as high-throughput 
studies, and helping to establish and test hypothesis trough data analyses. This essential 
task in drug discovery and in development cannot be accomplished with traditional 
approaches alone (Yang, 2010). 
System biology studies the interactions among biological elements toward the 
understanding of diseases at the system level (Yang, 2005). The combination of 
bioinformatics and systems biology approach can lead to a better understanding of immune-
related diseases (Rapin et al., 2006). 
With the comprehensive examination of structures, functions, and relationships between 
them at the molecular level, we can scale at the higher level to gain a more complete view of 
how the immune system work and interact with other systems. 
The understanding of changes in molecular and cellular pathways and interactions can be 
useful for finding new drug, target and designing effective drugs. These pathways are 
potential targets for developing novel therapeutics. 
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On the other hand, the structure-function analysis includes the examination of how 
sequence variants such as polymorphisms may have functional influences. Studies of 
transcription factors, functional motifs, 2D and 3D structure may help with the identification 
of epitopes and design of vaccines. These studies may shed light on the mechanisms of 
cellular pathways and protein-protein interactions. Advances in high-throughput analysis 
may greatly enhance such investigations. 
The perception at these points may contribute to the understanding of the interaction 
networks among humans, vaccines, drugs, and the environment and enable new insights of 
disease mechanisms and therapeutic responses. The integration of all of the information at 
various systems levels may ultimately lead to the development of optimized vaccines and 
drugs tailored to individualized prevention and treatment. 
3. Omics approach in allergy diseases 
Our knowledge of how genetic variation between subjects determines susceptibility, 
severity and response to treatment has expanded considerably, providing intriguing 
insights into the pathophysiology of these multifactorial disorders. The picture is complex 
but our understanding is exponentially increasing in the last years thanks to new 
technologies and bioinformatics tools.  
3.1 Genetic and genomic studies in allergy 
During the last 20 years many efforts were realized in order to identify protective factors 
that could increase the tolerance against allergens. The main objective of multiple 
investigations was to identify potential risk factors in the environment and to identify 
“allergy genes”.  
Classically there were two main approaches for searching genes related with 
asthma/allergy diseases: analysis of candidate genes or genome-wide screening, looking for 
new disease loci or genes (Ober & Hofman., 2006, Risk et al., 1996, Cárdaba et al., 1993, 
Carlson et al., 2004, Vercelli, 2008, Holloway et al., 2010). Population genetic studies like 
association studies and linkage analysis have played major roles in identification of several 
causative genes. Population genetic studies could be either hypothesis driven, which is the 
case in candidate gene studies, or with no prior hypothesis such as linkage studies. In 
candidate gene studies, genes are selected from the pathways shown or expected to play 
role in allergy disease pathogenesis. The advantage of this approach is that candidate genes 
have biological plausibility and often display known functional consequences that have 
potentially implications for the disease. Disadvantage is the limitations to discovery novel 
genes. Candidate gene studies could be based on allele frequency differences between 
affected and non-affected individuals (case-control studies) or based on transmission 
distortion or disequilibrium of allele(s) as in family based association studies (Cárdaba et al., 
2000, Cárdaba et al., 2002). Candidate genes are supposed to have high sensitivity to detect 
alleles or variants playing minor role in disease pathogenesis (Risk et al., 1996). Numerous 
association studies have been published (Vercelli, 2008, Ober &Hofman, 2006, Llanes et al., 
2009.), there are almost 1,000 studies that examine polymorphisms in several hundred genes 
including those involved an innate immunity (TLRs, CD14, CARD15, etc,), inflammation 
(e.g. various cytokines, chemokines, etc.), lung function, growth and development (TGFB1, 
ADRB2, NOS1 and SPINK5, etc.) and genes implicated as modifiers of responses to 
environmental exposures (GSTM1, GSTP1, GSTT1). Few candidate genes have been 
www.intechopen.com
New Challenges for Old Diseases:  
The Impact of -Omics Technologies in the Understanding of Allergic Diseases 
 
13 
consistently replicated: 54 genes in 2-5 independent samples, 15 genes in 6-10 independent 
samples and 10 genes in >10 independent samples (Ober &Hofman, 2006). 
Linkage studies are usually carried out to identify novel disease loci/genes by genotyping 
evenly markers in the entire genome, in large extended families. Approximately 20 genome-
wide linkage screens have been reported in different study populations to identify 
chromosomal regions linked to asthma/atopy and one or more allergy-phenotypic feature 
(Sleiman & Hakonarson, 2010). The lack of statistically power, differences in study design, 
and genetic differences in the populations studied could be the reason for low 
reproducibility of results. However, some chromosomal region demonstrated consisted 
linkage and contained genes biologically relevant in allergy, such as the cytokine cluster on 
chromosome 5q, FcεRI-β on 11q, IFN-γ and STAT6 on 12q, and IL4R-α on 16p. Linkage 
studies followed by positional cloning have identified novel genes which may influence 
susceptibility to asthma, including ADAM33, DPP10, PHF11 and GPRA (Sleiman 
&Hakonarson, 2010). 
Up to now, despite significant findings regarding susceptibility regions and genes in some 
cases, these studies have still resulted in only a very limited understanding of asthma and 
allergic diseases. Some of the reasons for the failure to replicate the detection of particular 
loci across studies and for the modest contribution of each of these susceptibility loci might 
relate to heterogeneity factors between studies that might be difficult to detect and take into 
account in small-scale studies (Von Mutius, 2004). However, there are some essential points 
that are well established by scientific community, as to recognize that few genes might have 
independent effects, as is typical for Mendelian diseases. It has become clear that the 
pathogenesis of complex polygenic disorders is dependent on multilayered gene-
environment interactions over time, in a model well described by Hersey (2004). 
Nonetheless, the approaches that have been used to find susceptibility genes, either through 
linkage or association studies, have for the most part considered one gene at a time. Despite 
this overly simplistic modelling of asthma and atopy genetics, many important discoveries 
have been made (Ober, 2005, Blumenthal, 2005).  
However, most recently, this kind of studies has been revolutionized by array-based SNP 
genotyping technologies and the characterization of millions of SNP variants in the human 
genome. This has made possible the simultaneous determination of the genotype of 
>500,000 SNPs throughout the genome of a subject. This has allowed the use of genome-
wide, hyphotesis-independent association studies that do not require the recruitment and 
phenotyping of large family-based samples and achieve greater statistically power for the 
same number of subjects. Genome wide association studies (GWASs) have become feasible 
in large cohorts of patients and controls. Using this approach, there are many evidences for 
genetic variants involved in different diseases (Sleiman &Hakonarson, 2010). 
GWAS approaches are based on the ability to rapidly analyze genetic variants (mainly 
single nucleotide polymorphisms (SNPs), usually with a high degree of heterozygosity) 
across the whole genome to determine which genetic variants are associated with disease 
susceptibility (case-control studies) or which are associated with measures of disease 
severity or response to treatment (ie, pharmacogenetics; case-only studies). GWASs are also 
performed in families, especially trios, which are defined as an affected child with 
genotyping from both parents but it is generally easier to ascertain and characterize a large 
number of unrelated cases and control subjects than to study multiple family members 
(Meyers, 2010). GWASs allows the identification of disease genes with only modest 
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increases in risk, a severe limitation in linkage studies and the very type of genes one 
expects for common disorders. 
To date, several GWASs have been performed with great success in allergic diseases, such as 
asthma, eczema, and allergic sensitization (Holloway et al., 2010). In mid-2007 the first 
application of GWA to bronchial asthma was the description of a novel asthma 
susceptibility locus contains the ORM1-like 3 (ORMDL3) and Gasdermin like (GSDML) 
genes on chromosome 17q12-21.1 (Moffatt et al., 2007). Importantly, subsequent studies 
have replicated the association between variation in the chromosome 17q21 region and 
asthma in ethnically diverse populations (Leung et al., 2009, Bisgaard et al., 2009, Wu et al., 
2010, Galanter et al., 2008, Tavendale et al., 2008). Further allergy-related phenotypes 
susceptibility genes have been discovered by GWAS as chromosome 5q12 at the region of 
the phosphodiesterase 4D (PDE4D) (Himes et al., 2009) involved in way smooth muscle 
concentration, an association with asthma and chromosome 1, at the region of DENND1B 
(gene that encodes for a protein that interact s with the TNF-α receptor) (Sleiman & 
Hakonarson , 2010). Using GWASs significant evidences were observed for asthma association 
and several genes as DPP10 (Mathias et al., 2010), TGFB1, IL1RL1 and CYFIP2 (Wu et al., 2010). 
In addition six studies have been reported (Sleiman & Hakonarson, 2010) using quantitative 
triat loci as intermediate phenotypes. A promoter SNP in the CHI3L1gene that encodes the 
chitinase-like protein (YKL-40) was shown to be a major determinant of elevated serum 
protein, being associated with asthma, bronchial responsiveness and pulmonary function 
(Ober et al., 2008), FCERA1A and RAD50 genes were associated with IgE levels and increased 
risk of asthma and atopic eczema (Weidinger et al., 2008), blood eosinophil counts was 
associated with five loci reached significance, one of which, IL1RL1 was also associated with 
asthma in a collection of different populations (Gudbjartsson et al., 2009). 
Finally, two large meta-analysis of lung function identified 11 candidate genes/regions. The 
first (Hancock et al., 2010) found that genes in the INTS12-GSTCD-NPNT region were 
associated with FEV1, and 8 genes (HHIP, GPR126, ADAM19, AGER-PPT2, FAM13A, 
PTCH1, P1D1 and HTR4) were associated with FEV1/forced vital capacity ratios. The second 
(Repapi et al., 2010) identified 4 genes (HHIP, GSTCD, TNS1 and HTR4) associated with 
FEV1 and 3 loci (HHIP, NOTCH4-AGER-PPT2, and THSD4) associated with FEV1/forced 
vital capacity ratios. The important question is to research the relationship among these 
regions and allergy-related phenotypes. 
In conclusion, with the recent advances in genotyping technology and the information 
provided by Human Genome and International HapMap projects, our ability to locate the 
genes underlying complex diseases has been dramatically improved. The results from 
GWASs are the first step. Replication studies are necessary, and meta-analyses are useful to 
determine the importance of these variants in multiple populations. However, in allergic 
diseases, environmental factors influence gene regulation/expression for that, gene-
environment interactions could be critical in these diseases (Cárdaba et al., 2007). In fact, in 
the last four years there has been an increase in the research of this field (review in Vercelli, 
2010b) and although the gene-environment interactions known to date have been identified 
through hypothesis-driven research and candidate gene approaches, several efforts are 
doing in order to develop novel analytical methods at allowing efficient testing for gene-
environment interactions in GWASs (Murcray et al., 2009, Chatterjee et al., 2009, Vineis et 
al., 2008). These studies could be a new era of gene-environment-wide interaction studies 
(GEWIS) (Khoury &Wacholder, 2009) that may change our understanding of gene-
environment interactions and their impact on complex disease susceptibility (Vercelli, 2010). 
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It is possible to group the genes identified until now as contributing to allergic disease into 4 
broad groups (Holloway et al., 2010): First, there is a group of genes that are identified are 
involved directly modulating response to environmental exposures. The second major 
group includes many of the genes identified by hypothesis-independent genome-wide 
approaches and is a group of genes involved in maintaining the integrity of the epithelial 
barrier at the mucosal surface and signalling to the immune system after environmental 
exposure. The third group are those that regulate the immune response, the TH1/TH2 
differentiation and effector functions, and others that might regulate the level of 
inflammation that occurs at the end organ for allergic disease. 
Finally, given the large amount of GWAS data available for many diseases, the results can 
be interrogated across studies to determine whether the same genes are being observed in 
different diseases, even if there is not known relationship between the diseases. After 
analysis of GWAS results from across 118 studies (Johnson & O´Donnell, 2009) evidence for 
the MHC region on chromosome 6 was observed across many studies, and genes involved 
in cell adhesion, signal transduction, and protein phosporilation were the most likely to be 
observed in different diseases entities. This bioinformatics approach can be useful for 
identifying potential similarities between disease processes that can be investigated further 
(Meyers, 2010). 
Anyway, functional biologic studies to understand the role of the identified genes, genetic 
variants and interactions are crucial to further our understanding of disease pathogenesis. 
3.2 Analysis of gene-expression or transcriptomic in allergic diseases 
Because microarray analysis is a more mature technique than the other approaches and 
because of the relative ease of working with nucleic acids, microarray remain the -omics 
technique that is most likely to have early applications in diagnosis or prognosis. 
One of the most popular omic-approach for disease gene identification has been the analysis 
of gene-expression by microarrays, which take advantage of the fact that transcript of 
various genes (until all the genome) can be assayed at large scale simultaneously (Rolph et 
al., 2006). Using both human subjects and animal models a number of studies have 
identified novel genes/pathways or validated others that play important role in asthma 
pathogenesis and may have therapeutic potentials (Rolph et al., 2006).  Combined with 
animal models this technology has played pivotal role in identification of genes/molecules 
involved in complex diseases. Animal models are suitable as confounding factors can be 
better controlled and tissue samples can be harvested sufficiently with easy. Also, identical 
genetic background of the inbred animal strains allow for dissection of environmental 
factors in influencing gene regulation in different pathological conditions (Kumar & Ghosh, 
2009).  
DNA microarrays can be used to compare differential gene-expression between control and 
case or patients before and after treatment, in order to find new genes and disease 
mechanisms and to define molecular signatures that can be useful in the diagnosis or 
classification of the disease and specific treatments. Major applications of this methodology 
have been related with cancer disease or single-genes disorders but in complex disorders, as 
allergic diseases, the number of studies is lower and only in the last years, this field is giving 
some interesting results.  
The first review of microarray technology in allergic diseases (Benson et al., 2004), described 
how some pioneers works identified differentially expressed genes between patient and 
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controls in allergic rhinitis or atopic dermatitis and how in a study of asthma, a combination 
of genes was showed to more accurately discriminate between the asthmatics and healthy 
controls than IgE (Brutsche et al., 2002). But most importantly, the authors remarked the 
distinctive characteristic of microarrays to identify whole groups of functionally related 
genes, rather than individuals, and the effects of specific cytokines relevant to allergy, as for 
example, the finding that a TH2 cytokine as IL-13, induce distinct transcriptional programs 
in different kind of cells (Lee et al., 2001), as well as pathways (Benson et al., 2002, 
Zimmermann et al., 2003). 
Most recently, interesting advances in allergic diseases has been associated with microarray 
studies. I would like to emphasis three major kinds of advances: Firstly the finding and 
verification of differentially expressed genes, with the description of many potential 
biomarkers and/or therapeutic targets that are still being validated, evaluated and explored 
with no clinical diagnostic or therapeutic benefit to date (Hansel et al., 2008,  Sääf AM et al., 
2008, Izuhara & Saito, 2006, Kuperman et al., 2005, Rolph et al., 2006, Tyner et al., 2006, 
Ricciardolo et al., 2005, Hansel & Diette, 2007, Woodruff et al., 2007, Hakonarson et al., 2005, 
Jones et al., 2009) but with a high potential. Secondly, the possibility to find molecular 
signatures associated with clinical subphenotypes, as has been demonstrated in asthma 
where at least two distinct molecular phenotypes defined by degree of TH2 inflammation 
were described (Woodruff et al., 2009). Interestingly, non-Th2–driven asthma represents a 
significant proportion of patients and responds poorly to current therapies. Most recently, 
gene expression patterns of TH2 inflammation and intercellular communication have been 
described in asthmatic airways (Choy et al., 2011). These results suggest that a predominant 
pattern of differential gene expression in asthma is related to TH2-driven airway 
inflammation; however, this pathway is linked to a large number of other factors associated 
with aspects of airway pathophysiology. An unsolved question is whether TH2 
inflammation is a cause or a consequence of the extended network of inflammatory and 
regulatory factors described as implicated. And finally, and interesting field is the 
possibility to discover dysregulated pathways by the analysis of modules that include 
tightly interacting genes, usually functional related genes. This approach was recently used 
to identify an inhibitory role for IL7R in allergic inflammation (Mobini et al., 2009). The gene 
expression profiles can be used to identify key regulatory networks, to identify novel 
potential candidate genes, and to define phenotypes, which can then serve as quantitative 
traits for genetic studies (Baye et al., 2010). An integrated genetic/genomic approach allows 
the mapping of the genetic factors that underpin individual differences in quantitative levels 
of expression. ArrayExpress and Gene Expression Omnibus are the two major public data 
repository for experimental microarray data with multiple gene annotations, including gene 
symbol, GO terms and disease associations. Integration of molecular and functional 
information it is necessary and the bioiformatic is an area essential for advancing in this 
field. With this integration, using publicly available gene expression datasets from multiple 
sources and tools a functional and regulatory map of asthma (Novershther et al., 2008) was 
described.  
An entire field of biology (Systems Biology) has emerged, with the goal of unravelling the 
complex networks of cells and signals underlying all biological processes. This ongoing 
exploration should lead to better tools to help us interpret gene expression microarray data 
and will ultimately allow us to leverage this technology in the diagnosis and treatment of 
diseases. 
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3.3 Use of protein microarrays in allergy  
DNA microarrays are limited to provide information on the identity or amount or RNA or 
DNA present in a sample. Translational products of genes can not be analyzed on such 
arrays and, therefore, require the use of polypeptide-based array. Most drug targets are 
proteins, therefore, protein and peptides microarrays are set to have an important impact on 
drug discovery. An important challenge when producing protein microarrays is 
maintaining functionality, such as post-transcriptional modifications and phosporylation.  
Due to the improvement in proteomics methodologies, several important proteomic 
applications have been used in allergy diseases (revised by Lucas, 2010). Basic research 
microarray technology has been used for the study of interactions among allergenic 
proteins, immunoglobulins and T cell receptors, with a view to developing genetic 
modifications which can yield hypoallergenic variants of plant proteins (Singh et al., 1999). 
Microarrays have been applied in the investigation of clonal diversity (Pinilla et al., 1999) 
and immune response heterogeneity among patients (Sheffler et al., 2005) and to establish 
the clinical correlations between antibody diversity and the allergic manifestations (Beyer et 
al., 2003, Chatschatee et al., 2001,). Microarray technology has been shown to be very useful 
for mapping and characterising allergenic epitopes (Lin et al., 2009). An example is 
represented by cow’s milk allergens with differentiation between IgE and IgG4 patterns for 
sequential epitopes of alpha (s1)-, alpha (s2)-, beta-and kappa-caseins and beta-lactoglobulin 
in reactive patients and tolerant individuals (Cerecedo et al., 2008).  
But one of the most important applications of proteomic in the allergy field is the microarray 
of allergic components that offer the possibility to study hundreds of allergenic components 
(recombinant or purified) in a single test, and using a very small amount of serum sample. 
This kind of studies or allergenic component-resolved diagnosis (CDR) microarrays, afford an 
image of patient sensitisation at molecular level, allowing the identification of the potential 
disease-eliciting molecules. This analysis led to the development of a new concept in allergy 
diagnosis: molecular diagnosis (Ferrer et al., 2009, Lindholm et al., 2006). Performance 
characteristics for allergens so far tested are comparable with the diagnostic tests currently 
used (Janh-Smith et al., 2003, Wohrl et al., 2006, Ott et al., 2008, Ebo et al., 2010). 
One of the most important utility of molecular diagnosis in allergy is its ability to reveal the 
allergens to which patients are sensitized, including primary or species-specific allergens 
and markers of cross-reactivity to proteins with similar protein structures may help to 
evaluate the risk of reaction on exposure to different allergen sources (Sastre, 2010). 
Using microarray-based testing makes it possible to determine the IgE reactivity profile of a 
patient and assess their clinical pattern. The whole profile can give complementary 
information to the results achieved by single allergen components or extract-based testing. 
In vitro test results should always be evaluated together with the clinical history, because 
allergen sensitization does not necessarily imply a clinical reaction.  The use of a predefined 
large number of allergen components in microarray systems can facilitate this task, although 
such an approach puts greater demands on interpretation. 
The use of IgE epitope mapping of allergens using microarray-based immunoassay will 
probably be the next step in development (Lin et al., 2009). 
Another area of research looks to establish whether information from molecular medicine 
can provide an indication as to the chances of tolerance development or if the allergy will be 
persistent. Molecular medicine can also be a support tool for adapting treatment strategy to 
the particularities of each patient in a timely manner, open the possibility of personalizing 
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the actions to be taken, as include targeted allergen exposure reduction advice, selection of 
suitable allergens for specific immunotherapy (SIT) or the need to perform food challenges. 
Although the fundamental role of two-dimensional gel electrophoresis combined with other 
proteomics techniques in the characterization of allergens, other proteomic approach as 
SELDI-TOF-MS has been useful for discovering biomarkers in asthma-related inflammation 
and remodelling, in a mice model (Calvo et al., 2009) and recently, the use of LC-MS/MS 
analysis combined with genomic expression analyses has been described for identifying 
novel potential markers of glucocorticoids treatment in intermittent allergic rhinitis (Wang 
et al., 2011). 
4. Conclusions 
In the last few years, our knowledge about of the human genome improved considerable. 
Still we are very far from the total understanding of the genomic background of complex 
diseases, but the news high-throughput technologies together with other complementary 
tools, as bioinfomatic, have contributed to highly increase our understanding of these 
complex disorders, and most importantly, have produced a change in the focusing of 
biological studies. The concept of biological systems open a broader, integrated view of 
biological system will yield a more complete understanding of disease, providing improved 
tools for identifying prognostic, diagnostic, biomarkers and treatment. 
However, we need many efforts before to design effective intervention in these diseases. 
New approaches and access to high quality, well-annotated datasets that will allow us to 
gain insight into novel process that we can associate with biological outcomes such as 
disease are needed. Microarray themselves provide only testable hypotheses, not firm 
conclusions, and validating is necessary. This complexity is reflect of the large number of 
new genes (and new splice variants and the expanding classes of noncoding RNAs) 
discovered by the ongoing sequencing of genomes and transcripts. Complicating this is the 
lack of information on molecular interactions; genes expression can only measure gene 
transcription, not translation, and certainly not the complex regulatory pathways and 
interactions leading to the array result, a snapshot of one sample at one moment. This leads 
to the current state of gene expression microarray data in asthma/allergy, where although 
many differentially expressed genes have been found and verify potential biomarkers 
and/or therapeutic targets are still being validated, evaluated and explored with no clinical 
diagnostic or therapeutic benefit to date. Molecular phenotyping of diseases, using 
technologies such as gene expression microarrays, has the potential to provide insights into 
the phenotypic heterogeneity of disease and the identification of associated biomarkers as 
well as strategies to select patients with an increased potential to respond to molecularly 
targeted therapies. However, the efficacy of molecularly targeted therapies in a clinical 
setting depends on both appropriate patient selection and appropriate outcome selection.  
We need to understand individual gene-gene, gene-protein, and protein-protein network 
interactions in human health and disease. An understanding of these networks should 
enable the opportunity to diagnose disease before it is clinically manifest or to define the 
targeted to be regulated. 
However, some areas have been considerable improvement with the high-throughput 
methodologies. Some microarray applications, as allergenic component microarrays offer an 
elegant way to avoid the problem of allergen standardisation and false polysensitisation. 
The possibility of determining specific IgE antibodies against multiple recombinants and 
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purified natural allergen components has allowed for the development of Molecular 
Diagnosis. This novel diagnostic technology is minimally invasive, makes use of small 
sample volumes, offers quantitative results, and constitutes a multianalytic test, thus 
facilitating its incorporation to clinical use. This technology opens the door to personalised 
medical practice, by allowing diagnosis and planning at molecular level, specific for each 
patient, with a known and balanced dosing of standardised allergens for immunotherapy. 
Molecular Diagnosis can be a support tool for reaching appropriate and timely clinical 
decisions on patients, which afford clinicians the possibility of individualizing the actions 
taken. 
In conclusion, although the advances in the understanding of molecular basis of allergic 
diseases have been highly improved by new “omics-approaches” and the potential it is 
undoubted, due to the complexity of this kind of diseases, many efforts before to design 
effective intervention are needed. These kinds of studies highlight the importance of 
understanding the underlying basis of heterogeneity in disease and the relationships 
between targeted pathways and in vivo patophysiology for developing strategies to identify 
patient populations with maximal potential benefit from molecularly targeted therapies. 
Besides, many other concepts as well as missing heritability (study of rare variants or minor 
allele frequency) gene-environment interactions, epigenetic effects, and well-defined 
consistent phenotypes across large population sets should be analyzed. Although the future 
is very promising and we have made great advances, still there is a long way to walk. 
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